Core Insights - Ronghe Medical Technology (Zhejiang) Co., Ltd. has completed a Series B financing round led by Qiming Venture Partners, with funds aimed at accelerating the clinical promotion and market expansion of its innovative "real-time electromagnetic navigation bronchial rheoplasty" technology for chronic obstructive pulmonary disease (COPD) [1][1][1] Company Overview - Ronghe Medical has developed the Breeze One® "real-time electromagnetic navigation pulsed electric field ablation system," which received FDA breakthrough device designation in April 2025 [1][1] - The company emphasizes its commitment to exploring life sciences and enhancing core innovative technologies to create significant clinical value [1][1] Investment Perspective - Qiming Venture Partners recognizes Ronghe Medical's original innovation in the field of COPD intervention, highlighting its clear clinical mechanisms and significant efficacy advantages, as well as its global competitiveness in "Chinese manufacturing" [1][1] - Huatang Venture Capital views Ronghe Medical as a model project of "medical-engineering integration," with high technical barriers and clinical recognition, and expresses anticipation for the company's global product expansion [1][1] Future Directions - Ronghe Medical plans to focus on the forefront of life sciences, integrating and expanding its core technology matrix to develop original medical device solutions with significant clinical value [1][1] - The company aims to enhance accessibility and equity in respiratory disease diagnosis and treatment, contributing to a more efficient and fair public health system [1][1]